Get it on Google Play

Anavex receives FDA feedback on Alzheimer's disease drug program

January 6, 2026 7:30 AM EST Send to a Friend
Anavex Life Sciences Corp. (NASDAQ: AVXL) announced that the U.S. Food and Drug Administration invited the company to present clinical ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login